Sleep Loss Sabotages the Brain’s Power Grid, but a Single Protein May Restore It

Sleep deprivation is one of the most common assaults on the modern brain, and scientists have long catalogued its toll: foggy thinking, weakened memory, inflamed neural tissue and disrupted metabolism. But a new study in mice has traced a surprisingly specific chain of molecular events that links a sleepless week to cognitive decline, and it points to a single protein that may be able to pull the brain back from the brink. The research, published in the Journal of Translational Medicine, identifies APPL1, a protein better known for its role in insulin signaling, as a central guardian of mitochondrial health in the hippocampus during sleep loss.

The team behind the work set out to answer a deceptively simple question: what actually breaks inside brain cells when sleep is withheld, and can the damage be reversed? Previous studies had established that sleep deprivation disrupts glucose metabolism, damages mitochondria and triggers neuroinflammation, but the molecular pathway connecting these phenomena remained murky. APPL1 was a compelling candidate because it regulates insulin sensitivity and exerts anti-inflammatory effects in peripheral tissues, yet almost nothing was known about what it does in the brain under conditions of sleep deprivation.

To find out, the researchers subjected C57BL/6 mice to seven days of sleep deprivation and then used adeno-associated viral vectors to overexpress APPL1 specifically in hippocampal neurons. This is a crucial detail of the experimental design: rather than altering the protein throughout the body, the team targeted the brain region most closely associated with memory and learning. They then assessed mitochondrial dynamics, glucose metabolism, neural morphology and cognitive function using a battery of techniques including immunofluorescence, electron microscopy, western blotting, Golgi staining and behavioral testing.

The picture that emerged from the sleep-deprived mice was grim. The animals showed significant impairments in glucose metabolism and marked disruptions in mitochondrial morphology, along with substantial weight loss and elevated levels of pro-inflammatory cytokines, including tumor necrosis factor-alpha, interleukin-6 and interleukin-1 beta, in the hippocampus. Equally telling was what had disappeared: the expression of key mitochondrial regulators, among them APPL1 itself, Rab32, phosphorylated DRP1 at the Ser637 residue, and cytochrome c oxidase subunit IV, or COX4, was notably diminished. In other words, sleep loss did not merely damage mitochondria; it appeared to strip away the very proteins that keep them healthy.

Mitochondria are not static organelles. They constantly fuse, divide and redistribute themselves in response to cellular demands, a process known as mitochondrial dynamics. When that balance collapses, energy production falters, reactive oxygen species accumulate and neurons begin to fail. The downregulation of p-DRP1, a phosphorylated form of dynamin-related protein 1 that helps govern mitochondrial fission, and COX4, a core component of the electron transport chain, suggested that sleep-deprived neurons were losing both the architectural control and the metabolic machinery of their power supplies.

To dissect the mechanism at the cellular level, the researchers turned to primary neurons exposed to lipopolysaccharide, an inflammatory stimulus that mimics some of the molecular stress of sleep deprivation. When APPL1 was activated in these neurons, it promoted its own colocalization with Rab32, a protein previously implicated in mitochondrial dynamics, and set off a cascade of restorative effects. Levels of p-DRP1 and COX4 rose, malondialdehyde, a marker of lipid peroxidation and oxidative damage, fell, and the activities of the antioxidant enzymes superoxide dismutase and glutathione peroxidase increased. Together, these changes restored mitochondrial function, morphology and network integrity. The clincher came when the team knocked down Rab32: every one of APPL1’s beneficial effects vanished, demonstrating that Rab32 is not merely a bystander but an essential mediator of the pathway.

Two independent techniques confirmed the physical relationship between the proteins. Co-immunoprecipitation showed that APPL1 and Rab32 associate with each other inside cells, while molecular docking studies predicted a structurally plausible binding interface between the two molecules. This convergence of biochemical and computational evidence strengthens the case that APPL1 acts directly through Rab32 rather than through some parallel route, and it places the APPL1-Rab32-p-DRP1 axis at the heart of mitochondrial maintenance in stressed neurons.

The in vivo results were equally striking. When APPL1 was overexpressed in the hippocampal neurons of sleep-deprived mice, Rab32 expression in the hippocampus improved, mitochondrial and neuronal morphology were restored, neuroinflammation subsided and cognitive deficits eased. Behavioral tests, including the novel object recognition test, reflected genuine functional recovery rather than mere biochemical correction. The authors also explored a translational angle: they engineered a recombinant fusion protein, TAT-APN, which combines the cell-penetrating TAT peptide, derived from the transactivator of transcription protein, with the N-terminal region of APPL1. The TAT tag is famous for its ability to cross the blood-brain barrier, and the team’s analyses suggest that TAT-APN can serve as a therapeutic agent to improve cognitive function in sleep-deprived mice, offering a potential route toward protein-based treatment.

What makes the study conceptually important is the bridge it builds between two usually separate research worlds: mitochondrial dysfunction and insulin resistance. APPL1 sits at the intersection of both. In peripheral tissues it enhances insulin signaling, and in the brain it now appears to protect mitochondria through Rab32. The authors argue that their findings emphasize the interplay between mitochondrial dysfunction and insulin resistance in the brain in the context of cognitive impairment, a framing that resonates with growing interest in the metabolic roots of neurological disease. Conditions ranging from Alzheimer’s disease to shift-work-related cognitive decline involve both metabolic dysregulation and mitochondrial failure, and a pathway that connects them offers a unified target.

There are, of course, the usual caveats that separate mouse studies from human medicine. Seven days of enforced sleep deprivation in a laboratory mouse is an extreme model, and the therapeutic candidate, TAT-APN, has so far been evaluated only in animals, with purification support from a commercial partner in Wuhan. The work was funded by the National Natural Science Foundation of China, the Liaoning Provincial Natural Science Foundation and a Dalian municipal health program, reflecting a sustained institutional bet on sleep and metabolism research. Still, the study delivers something rare in the field: a complete mechanistic arc, from a behavioral symptom to a molecular interaction to a candidate drug, all documented within a single paper. If the APPL1-Rab32 pathway holds up in further studies, the prospect of a molecule that can slip through the blood-brain barrier and reboot the brain’s mitochondrial dynamics after sleep loss would transform how we think about the cost of a sleepless week, and how we might pay it back.

Subject of Research: How the protein APPL1 regulates mitochondrial dynamics via Rab32 to alleviate cognitive deficits caused by sleep deprivation in mice

Article Title: APPL1, a novel protein, alleviates cognitive deficits via Rab32-mediated mitochondrial dynamics in a mouse model of sleep deprivation

Article References: Li, L., Mou, Y., Gao, X., Zhai, Y., Zhang, X., Wang, Q., & Xiao, Z. (2026). APPL1, a novel protein, alleviates cognitive deficits via Rab32-mediated mitochondrial dynamics in a mouse model of sleep deprivation. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08975-5

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08975-5

Keywords: sleep deprivation, APPL1, Rab32, mitochondrial dynamics, cognitive function, hippocampus, neuroinflammation, brain insulin resistance, p-DRP1, TAT-APN, oxidative stress, C57BL/6 mice